Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Shares Shorted: Short Interest Up 200.8% in October

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a significant increase in short interest in October. As of October 30th, there was short interest totaling 47,382 shares, an increase of 200.8% from the October 15th total of 15,751 shares. Based on an average daily trading volume, of 1,264,801 shares, the short-interest ratio is presently 0.0 days. Approximately 2.7% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Thursday, October 15th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Bolt Biotherapeutics currently has a consensus rating of “Hold” and an average target price of $14.50.

Insider Activity at Bolt Biotherapeutics

In other Bolt Biotherapeutics news, CEO William P. Quinn sold 9,132 shares of the company’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $3.24, for a total value of $29,587.68. Following the sale, the chief executive officer owned 25,384 shares of the company’s stock, valued at approximately $82,244.16. This represents a 26.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Coastlands Capital Lp bought 50,000 shares of the stock in a transaction on Monday, November 9th. The stock was purchased at an average cost of $6.38 per share, for a total transaction of $319,000.00. Following the acquisition, the insider directly owned 462,416 shares of the company’s stock, valued at $2,950,214.08. The trade was a 12.12% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 38,584 shares of company stock valued at $128,361 over the last ninety days. 9.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bolt Biotherapeutics

An institutional investor recently bought a new stake in Bolt Biotherapeutics stock. Nan Fung Group Holdings Ltd bought a new position in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,000 shares of the company’s stock, valued at approximately $19,250. Bolt Biotherapeutics accounts for 0.0% of Nan Fung Group Holdings Ltd’s holdings, making the stock its 25th biggest holding. Nan Fung Group Holdings Ltd owned about 0.26% of Bolt Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Price Performance

Shares of Bolt Biotherapeutics stock traded up $0.17 during trading on Friday, hitting $6.08. 28,108 shares of the company were exchanged, compared to its average volume of 746,433. Bolt Biotherapeutics has a fifty-two week low of $3.10 and a fifty-two week high of $7.78. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 1.47. The firm has a 50 day moving average price of $4.63 and a 200 day moving average price of $4.51. The stock has a market capitalization of $11.73 million, a price-to-earnings ratio of -0.41 and a beta of 0.85.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Thursday, November 12th. The company reported ($2.25) EPS for the quarter, beating analysts’ consensus estimates of ($3.68) by $1.43. The firm had revenue of $0.45 million for the quarter, compared to analysts’ expectations of $0.45 million. Bolt Biotherapeutics had a negative return on equity of 132.36% and a negative net margin of 611.47%. On average, equities analysts expect that Bolt Biotherapeutics will post -11.10 earnings per share for the current fiscal year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.